Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCAINAMIDE HCL vs NORPACE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
Treatment of documented ventricular arrhythmias (e.g., sustained ventricular tachycardia) that are life-threatening,Off-label: Atrial fibrillation, atrial flutter, supraventricular tachycardia, Wolff-Parkinson-White syndrome
Treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia,Off-label: Atrial fibrillation, atrial flutter, supraventricular tachycardia
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Hepatic via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); also undergoes hydrolysis to p-aminobenzoic acid.
Extensively metabolized in the liver primarily by CYP2D6; also involves CYP1A2 and CYP3A4 to a minor extent. Active metabolite: desethylnorpace.
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
15-25% bound primarily to alpha-1-acid glycoprotein and albumin.
80-90%, primarily to alpha-1-acid glycoprotein and albumin.
1.5-2.5 L/kg (approximates total body water; indicates extensive tissue distribution).
1.8-3.6 L/kg; large, indicating extensive tissue distribution.
Oral: 75-95% (immediate-release); IM: 100%; IV: 100%.
Oral: 80-90%.
Cr Cl >50 m L/min: No adjustment. Cr Cl 10-50 m L/min: Administer every 6-12 hours. Cr Cl <10 m L/min: Administer every 12-24 hours.
GFR 30-50 m L/min: 150 mg every 12-24 hours; GFR 15-29 m L/min: 150 mg every 24-48 hours; GFR <15 m L/min (not on dialysis): 150 mg every 48 hours or 100 mg every 24 hours.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50%. Child-Pugh Class C: Reduce dose by 50-75% or avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50% with monitoring; Child-Pugh Class C: contraindicated or use with extreme caution.
IV: Loading dose: 15 mg/kg over 30-60 minutes, followed by maintenance infusion of 20-80 mcg/kg/min; maximum 2 g/day. Oral: 15-50 mg/kg/day in divided doses every 3-6 hours; maximum 4 g/day.
<1 year: 10-30 mg/kg/day divided every 6 hours; 1-4 years: 10-30 mg/kg/day divided every 6 hours; 4-12 years: 10-30 mg/kg/day divided every 6 hours; 12-18 years: 150-300 mg every 6 hours. Maximum 800 mg/day.
Start at lower end of dosing range due to age-related decreased renal function and increased risk of hypotension and arrhythmias. Monitor renal function and adjust accordingly.
Initiate at 100 mg every 6 hours; consider lower doses due to age-related renal decline; monitor for anticholinergic effects and QT prolongation.
Procanamide can cause agranulocytosis, leukopenia, and thrombocytopenia; fatal blood dyscrasias have occurred. Frequent blood counts are recommended.
None
May cause lupus erythematosus-like syndrome (especially with slow acetylator phenotype); proarrhythmic effects (torsades de pointes); hypotension; bone marrow suppression; hepatotoxicity; potentiation of neuromuscular blocking agents.
Proarrhythmic effects (e.g., new or worsened arrhythmias, torsades de pointes),Heart failure exacerbation,Hepatic impairment,Renal impairment,Electrolyte disturbances (hypokalemia, hypomagnesemia),Conduction disturbances (e.g., QT prolongation, heart block)
Complete heart block; second- or third-degree AV block without pacemaker; long QT syndrome; torsades de pointes; known hypersensitivity to procainamide or any component.
Pre-existing second- or third-degree AV block unless pacemaker is present,Cardiogenic shock,Severe heart failure,QTc interval > 450 ms,Concomitant use of other QT-prolonging drugs,Hypersensitivity to disopyramide or any component
No significant food interactions reported. However, changes in dietary salt intake may affect blood pressure control; avoid excessive caffeine or alcohol as they may trigger arrhythmias. Maintain consistent potassium and magnesium intake; severe electrolyte disbalances can alter drug effect.
Grapefruit juice may increase disopyramide levels; avoid concurrent intake. High-fat meals may delay absorption; take consistently with or without food. Avoid excessive alcohol, which can exacerbate hypotension and arrhythmias.
FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use only if clearly needed. In second and third trimesters, chronic use may be associated with fetal bradycardia, QT prolongation, and neonatal lupus syndrome (transient). Avoid in pregnancy if possible.
First trimester: No evidence of increased risk of congenital malformations in human studies, but animal studies are insufficient. Second and third trimesters: Risk of fetal bradycardia, QT prolongation, and neonatal depression at delivery. Disopyramide may stimulate uterine contractions, increasing risk of preterm labor.
Procainamide and its active metabolite NAPA are excreted into breast milk. Milk-to-plasma ratio is approximately 0.8-1.3. Concentrations in milk can reach therapeutic levels. Potential for adverse effects in nursing infant, including bradycardia and hypotension. Use with caution, monitor infant. AAP recommends avoiding use if possible.
Disopyramide is excreted in breast milk with an M/P ratio of approximately 1:1.1. The relative infant dose is about 2–10% of the maternal weight-adjusted dose. Monitor infant for bradycardia, QT changes, and hypoglycemia. Alternative agents preferred unless benefit outweighs risk.
Pregnancy alters pharmacokinetics: increased volume of distribution may require higher loading doses (25-30% increase). Decreased plasma albumin reduces protein binding, increasing free fraction. Enhanced renal clearance (due to increased GFR) may necessitate more frequent dosing or dose adjustments. Monitor serum concentrations closely. Start with oral doses of 50 mg/kg/day in divided doses, titrate to effect. Intravenous: initial 100 mg every 5 minutes until arrhythmia controlled, then maintenance 2-6 mg/min with adjustments.
Increased renal clearance and volume of distribution in pregnancy may reduce disopyramide serum concentrations. Therapeutic drug monitoring recommended; dose adjustments may be required to maintain efficacy, but empirical increases are not routinely recommended due to risk of uterine contractions and fetal effects. Plasma protein binding is unchanged.
Procainamide HCL is a Class IA antiarrhythmic used for atrial and ventricular arrhythmias. It can cause lupus-like syndrome, especially in slow acetylators; monitor ANA titers. Renal dose adjustment is critical due to active metabolite N-acetylprocainamide (NAPA) accumulation. Watch for QT prolongation and torsades de pointes; avoid with other QT-prolonging drugs. Administer IV slowly to avoid hypotension; oral loading requires hepatic first-pass consideration.
NORPACE (disopyramide) is a Vaughan Williams Class Ia antiarrhythmic with negative inotropic effects; avoid in patients with heart failure or reduced LVEF. Monitor QRS and QT intervals; torsades de pointes risk. Adjust dose in renal impairment. Anticholinergic side effects (dry mouth, urinary retention, blurred vision) are common.
Take this medication exactly as prescribed; do not double doses if missed.,Report any symptoms of lupus (joint pain, rash, fever, chest pain) immediately.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Tell your doctor all other medications, especially other heart rhythm drugs.,You may need regular blood tests to monitor drug levels and organ function.,Do not stop taking this medicine abruptly; sudden stop may worsen arrhythmia.,If using extended-release tablets, do not crush or chew them.
Take exactly as prescribed; do not miss doses or double up.,Avoid driving if you experience blurred vision or dizziness.,Report chest pain, shortness of breath, fainting, or rapid heartbeat immediately.,May cause dry mouth; sugarless gum or candy can help.,Avoid alcohol and grapefruit juice without consulting your doctor.,Do not stop abruptly; gradual tapering may be needed.
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCAINAMIDE HCL vs NORPACE, answered by our medical review team.
PROCAINAMIDE HCL is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.. NORPACE is a Antiarrhythmic (Class Ia) that works by Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCAINAMIDE HCL and NORPACE depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCAINAMIDE HCL is: For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.. The standard adult dose of NORPACE is: 150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCAINAMIDE HCL and NORPACE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCAINAMIDE HCL is classified as Category A/B. FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use onl. NORPACE is classified as Category C. First trimester: No evidence of increased risk of congenital malformations in human studies, but animal studies are insufficient. Second and third trimesters: Risk of fetal bradyca. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.